| Overview |
| bs-70163R |
| Mnk2b Antibody |
| WB |
| Specific for endogenous levels of the ~47 kDa Mnk2b protein. Immunolabeling is blocked by preadsorption with the Mnk2b peptide used as antigen, but not by Mnk2a peptide. |
| Human |
| Non-Human Primate |
| Specifications |
| Unconjugated |
| Rabbit |
| Synthetic peptide from the C-terminal region, specific to the human Mnk2b isoform. The sequence of the antigen has no homology with Mnk1 or Mnk2a. |
| Polyclonal |
| IgG |
| Lot Dependent |
| Antigen Affinity purification from Pooled whole antiserum |
| 10 mM HEPES (pH 7.5), 150 mM NaCl, 100 µg per ml BSA and 50% glycerol. |
| Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C. |
| Target |
| 2872 |
| Q9HBH9 |
| MADS box transcription enhancer factor 2 antibody, MDS1 EVI1 antibody, Mef2b antibody, MEF2B_HUMAN antibody, Myocyte enhancer factor 2B antibody, Myocyte specific enhancer factor 2B antibody, Myocyte-specific enhancer factor 2B antibody, PRDM3 antibody, RSRFR2 antibody, whole antiserum response factor like protein 2 antibody, whole antiserum response factor-like protein 2 antibody, XMEF2 antibody |
| MAP kinase-interacting kinases Mnk1 and Mnk2, are activated by the MAP kinases, ERK and p38 (Waskiewicz et al., 1997). Additionally, Mnk1 and Mnk2 have been shown to phosphorylate the translation initiation factor eIF4E (Fukunaga and Hunter 1997; Waskiewicz et al., 1997). Alternative splicing of the MKNK2 gene results in two isoforms with different C-termini: one that has a MAPK-binding domain, Mnk2a, and one that does not, Mnk2b (Parra et al., 2005). Recent studies have indicated that Mnk2a has tumor suppressive activity while Mnk2b is pro-oncogenic (Maimon et al., 2014). |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz